Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Inclusion Criteria: * male or female subjects aged between 35 and 70 years, inclusive * type 2 diabetes with duration \>6 months and \<10 years * for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas * HbA1c \>=7.0% and \<=10.0% * if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start * written informed consent Exclusion Criteria: * history or presence of cancer or any clinically relevant diseases * chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial infarction within the previous 6 months * recurrent hypoglycemia * abnormal lab tests at screening (ALAT and/or ASAT \>=3 times ULN), creatinine \>1.6 mg/dL in males and \>1.4 mg/dL in females * clinically relevant ECG findings at screening * treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months * treatment with any other OHA than metformin or metformin plus sulfonylureas during the previous 3 months * any systemic or topical treatment with drugs known to influence glucose metabolism